PremiumRatingsOptimistic Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trial Developments Apogee Therapeutics Reports 2024 Financial Results and Pipeline Progress Apogee Therapeutics price target raised to $116 from $110 at Guggenheim PremiumThe FlyOruka Therapeutics initiated with an Outperform at Wolfe Research Apogee Therapeutics Advances APG777 in Key Phase 2 Trial Apogee announces first patient dosed in Part B of Phase 2 APEX trial PremiumCompany AnnouncementsApogee Therapeutics Advances in I&I Disease Treatments Apogee Therapeutics highlights progress at 2024 Inaugural R&D Day Apogee Therapeutics plans to take combination approach to AD 
